Liao S, Wang B, Zeng R, et al. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res. 2021;82(8):1096–110.

Article  CAS  PubMed  Google Scholar 

Schipilliti FM, Drittone D, Mazzuca F, et al. Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer. Heliyon. 2024. https://doi.org/10.1016/j.heliyon.2024.e28385.

Article  PubMed  PubMed Central  Google Scholar 

Shastry M, Jacob S, Rugo HS, et al. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169–77.

Article  PubMed  PubMed Central  Google Scholar 

Daiichi Sankyo. DATROWAY® approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer [media release]. 27 Dec 2024. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202412/20241227_E.pdf.

Daiichi Sankyo. DATROWAY® for intravenous drip infusion 100mg: Japanese prescribing information. 2025. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/430574_42914F9D1024_1_01#HDR_Warnings. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_42914F9D1024_1_01. Accessed 25 Mar 2025.

Daiichi Sankyo I, AstraZeneca Pharmaceuticals LP. DATROWAY® (datopotamab deruxtecan-dlnk) for injection, for intravenous use: US prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761394s000lbl.pdf. Accessed 25 Mar 2025.

Daiichi-Sankyo. DATROWAY® approved in the U.S. for patients with previously treated metastatic HR positive, HER2 negative breast cancer [media release]. 17 Jan 2025. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202501/20250117_E.pdf.

Daiichi Sankyo. DATROWAY® approved in the EU for patients with previously treated metastatic HR positive, HER2 negative breast cancer [media release]. 8 Apr 2025. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202504/20250408_E2.pdf.

Health Canada. Drug and health product Submissions Under Review (SUR): new drug submissions under review. 2025. https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/submissions-under-review/new-drug-submissions-under-review.html#tbl1. Accessed 25 Mar 2025.

AstraZeneca. Q1 2024 results [media release]. 25 Apr 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html#:~:text=Pascal%20Soriot%2C%20Chief%20Executive%20Officer,19%25%20in%20the%20first%20quarter.

AstraZeneca. Datopotamab deruxtecan granted priority review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer [media release]. 13 Jan 2025. https://www.astrazeneca-us.com/media/press-releases/2025/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer.html.

Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20(12):2329–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam F, Yuca E, Evans KW, et al. Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin Cancer Res. 2024;31(3):573–87.

Article  PubMed Central  Google Scholar 

Bardia A, Krop IE, Kogawa T, et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42(19):2281–94.

Article  CAS  PubMed  Google Scholar 

Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41(29):4678–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Xiao Z, Cheng Y, et al. Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): results from the phase 1/2 TROPION-PanTumor02 study [abstract no. 8548 plus poster]. J Clin Oncol. 2024;42(16 Suppl).

Bardia A, Jhaveri K, Im SA, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2024;43(3):285–96.

Article  PubMed  Google Scholar 

Pistilli B, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptorpositive, HER2-negative (HRD/HER2e) breast cancer (BC): final overall survival (OS) from the phase III TROPION-Breast01 trial [abstract no. VP1-2025]. Ann Oncol. 2025;36(3):348–50.

Bartsch R, Berghoff AS, Furtner J, et al. Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2) [abstract no. 187P]. ESMO Open. 2024;9(Suppl 4):10–1.

Schmid P, Jung K, Wysocki P, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study [abstract no. 166MO]. Ann Oncol. 2022;33:S199.

Schmid P, Wysocki PJ, Ma CX, et al. Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ib/II study [abstract no. 379MO]. Ann Oncol. 2023;34:S337.

Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2024;43(3):260–72.

Article  PubMed  Google Scholar 

Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025. https://doi.org/10.1200/jco-24-01349.

Article  PubMed  Google Scholar 

Planchard D, Cozic N, Wislez M, et al. ICARUS-LUNG01: a phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome [abstract no. 8501]. J Clin Oncol. 2024;42(16 Suppl).

Daiichi Sankyo Company. Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 phase 3 trial [media release]. 9 Sep 2024. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202409/20240909_E.pdf.

Sands J, Lisberg A, Bardia A, et al. Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd) [abstract no. 8623]. J Clin Oncol. 2024;42(16 Suppl).

McArthur H, Tolaney S, Loibl S, et al. TROPION-Breast04: a phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer [abstract no. PO1-20-13]. Cancer Res. 2024;84(9 Suppl).

Bardia A, Pusztai L, Albain K, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024. https://doi.org/10.1177/17588359241248336.

Article  PubMed  PubMed Central  Google Scholar 

Dent RA, Cescon DW, Bachelot T, et al. TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19(35):2349–59.

Article  CAS  PubMed  Google Scholar 

Schmid P, Oliveira M, O'Shaughnessy J, et al. TROPION-Breast05: phase (ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) [abstract no. 261TiP]. In: ESMO Open. 2024.

Aggarwal C, Cheema P, Arrieta O, et al. AVANZAR: phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC [abstract no. P2.04-02]. J Thorac Oncol. 2023;18(11):S305-S6.

Okamoto I, Kuyama S, Girard N, et al. TROPION-Lung07: phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20(37):2927–36.

Article  PubMed  PubMed Central  Google Scholar 

Levy BP, Felip E, Reck M, et al. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023;19(21):1461–72.

Article  CAS  PubMed  Google Scholar 

Janjigian Y, Oaknin A, Lang J, et al. TROPION-PanTumor03: phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors [abstract no. TPS3153]. J Clin Oncol. 2023;41(16 Suppl).